title: Botulinum neurotoxin type B and physical therapy in the treatment of piriformis syndrome: a dose-finding study.
abstract: OBJECTIVE
  To measure dosage effects of botulinum neurotoxin type B with physical therapy in piriformis syndrome.
  
  
  METHODS
  Prospective study of consecutive patients complaining of buttock pain and sciatica, measuring serial H-reflex tests in flexion, adduction, and internal rotation; visual analog scale; and adverse effects at 0, 2, 4, 8, and 12 wks. We used an electrophysiologic criterion for piriformis syndrome: a 1.86-msec prolongation of the H-reflex with the flexion, adduction, and internal rotation test. Four piriformis syndrome groups were identified. Serial groups were injected once with either 5000, 7500, 10,000, or 12,500 units of botulinum neurotoxin type B in successive months under electromyographic guidance in four separate locations of the affected piriformis muscle, with a 1-mo safety observation period between groups. Patients received physical therapy twice weekly for 3 mos.
  
  
  RESULTS
  The flexion, adduction, and internal rotation test and visual analog scale declined significantly, correlating at 72% sensitivity and 77% specificity. A total of 24 of 27 study patients had >/=50% pain relief. Mean visual analog scale score declined from 6.7 to 2.3. A volume of 12,500 units of botulinum neurotoxin type B was superior to 10,000 units at 2 wks postinjection. The most severe adverse effects were dry mouth and dysphagia, approaching 50% of patients at 2 and 4 wks.
  
  
  CONCLUSIONS
  Physical therapy and 12,500 units of botulinum neurotoxin type B seem to be safe and effective treatment for piriformis syndrome. In addition, the flexion, adduction, and internal rotation test seems to be an effective means of diagnosing piriformis syndrome and assessing its clinical improvement. Injection may benefit patients for >3 mos.
authors.affiliation: Columbia College of Physicians and Surgeons, New York, New York, USA.
authors.forename: Loren M
authors.initials: LM
authors.lastname: Fishman
authors.forename: Craig
authors.initials: C
authors.lastname: Konnoth
authors.forename: Bernard
authors.initials: B
authors.lastname: Rozner
mesh_terms: D001905:Botulinum Toxins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D002081:Buttocks; D004305:Dose-Response Relationship, Drug; D004568:Electrodiagnosis; D006181:H-Reflex / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010147:Pain Measurement; D026741:Physical Therapy Modalities; D011446:Prospective Studies; D012585:Sciatica / Q000175:diagnosis / Q000503:physiopathology / Q000534:rehabilitation*; D013577:Syndrome
chemical_list: D009465:Neuromuscular Agents; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A